Effects of Semaglutide on Neurological and Psychiatric Outcomes in Type 2 Diabetes
Author Information
Author(s): De Giorgi Riccardo, Koychev Ivan, Adler Amanda I., Cowen Philip J., Harmer Catherine J., Harrison Paul J., Taquet Maxime
Primary Institution: University of Oxford
Hypothesis
Does semaglutide use increase the risk of neurological and psychiatric outcomes compared to other antidiabetic medications?
Conclusion
Semaglutide is not associated with an increased risk of neurological and psychiatric outcomes and may even reduce the risk of cognitive deficits and nicotine misuse.
Supporting Evidence
- Semaglutide was associated with a reduced risk of cognitive deficit compared to sitagliptin and glipizide.
- Semaglutide showed a lower risk of nicotine misuse across all comparisons.
- No increased risk of neurological or psychiatric outcomes was found with semaglutide use.
Takeaway
This study found that taking semaglutide for diabetes doesn't make you more likely to have brain or mental health problems, and it might even help with thinking and smoking issues.
Methodology
Retrospective cohort study using electronic health records from TriNetX US Collaborative Network, comparing semaglutide with sitagliptin, empagliflozin, and glipizide.
Potential Biases
Residual confounding may exist due to unmeasured socioeconomic and lifestyle factors.
Limitations
Potential coding errors in electronic health records and inability to assess medication adherence.
Participant Demographics
Mean age 56.6 years, 48.6% female.
Statistical Information
P-Value
p<0.0001
Confidence Interval
95% CI 0.64–0.80 for cognitive deficit compared to sitagliptin
Statistical Significance
p<0.0023
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website